Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Learn about nyse:ABBV with our data and independent analysis including share price, star rating, valuation, dividends, and financials.

The author includes U.S. and Canadian names, organized by country. Each company comes with a business summary, plus a bull ...

Tremfya snagged Dupixent’s place as the pharma brand with the most TV impressions in June, according to data released by iSpot.tv on Friday morning. The Johnson & Johnson brand garnered a 4.3% share ...

Medtronic is approaching five decades of dividend growth. AbbVie rose to the challenge when its Humira patent expired, ...

Leading companies, such as Incyte Corporation, TWi Biotechnology, Amgen, Pfizer, Arcutis Biotherapeutics, AnaptysBio, and others, are actively advancing promising drug candidates aimed at improving ...

We came across a bullish thesis on AbbVie Inc. on Dividend Talks’s Substack. In this article, we will summarize the bulls’ ...

Advancements in itch therapeutics have evolved rapidly, offering patients with various itch-driven diseases multiple options that target the source of their itch. Itch exists on a spectrum, according ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

A small percentage of people with ankylosing spondylitis also develop Crohn’s disease or ulcerative colitis. Learn why and what treatments may work.

Leonard Calabrese, DO, Paras Karmacharya, MD, MS, and Adam Kilian, MD, explore how the older average age of patients with GCA ...

SNS Insider Reveals Sharp Growth in U.S. Retinal Biologics Market, Valued at USD 9.70 Billion in 2023 Capturing Over 43% Global Share Amid FDA Approvals, VEGF-A Dominance, and Accelerating R&D in ...